VLA15 for lyme disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 28 Jul 2022: Trial registered, NCT05477524
  2. 4 Aug 2022: Trial started, NCT05477524
  3. 2 Dec 2022: Trial registered, NCT05634811
  4. 12 Dec 2022: Trial started, NCT05634811

The trials

NCT05477524: An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

State
Completed
Phase
Phase 3
People
12,546 taking part
Started
4 Aug 2022
Primary completion
7 Jan 2026
Arms
VLA15 Lot 1 (3-dose primary vaccination series and booster dose), VLA15 Lot 2 (3-dose primary vaccination series and booster dose), VLA15 Lot 3 (3-dose primary vaccination series and booster dose)
Results
None posted
  1. 28 Jul 2022: Trial registered
  2. 4 Aug 2022: Trial started
  3. 7 Jan 2026: Trial completed

NCT05634811: Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

State
Completed
Phase
Phase 3
People
3,547 taking part
Started
12 Dec 2022
Primary completion
21 Jul 2025
Arms
VLA15
Results
Posted on the registry
  1. 2 Dec 2022: Trial registered
  2. 12 Dec 2022: Trial started
  3. 21 Jul 2025: Trial completed
  4. 7 May 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.